Carmelo Bernabeu Selected Research

Hereditary Hemorrhagic Telangiectasia

1/2022	Functional Alterations Involved in Increased Bleeding in Hereditary Hemorrhagic Telangiectasia Mouse Models.
12/2021	Homozygous GDF2 nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an "HHT-like" syndrome in children.
5/2019	Characterization of a mutation in the zona pellucida module of Endoglin that causes Hereditary Hemorrhagic Telangiectasia.
4/2019	Characterization of a family mutation in the 5' untranslated region of the endoglin gene causative of hereditary hemorrhagic telangiectasia.
1/2019	Endoglin as an Adhesion Molecule in Mature and Progenitor Endothelial Cells: A Function Beyond TGF-β.
1/2019	Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners.
1/2018	Human endoglin as a potential new partner involved in platelet-endothelium interactions.
1/2018	Soluble endoglin regulates expression of angiogenesis-related proteins and induction of arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasia.
10/2017	Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.
4/2016	Endoglin regulates mural cell adhesion in the circulatory system.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carmelo Bernabeu Research Topics

Disease

26	Hereditary Hemorrhagic Telangiectasia 01/2022 - 11/2004
15	Inflammation (Inflammations) 08/2021 - 03/2003
6	Neoplasms (Cancer) 01/2019 - 01/2007
5	Arteriovenous Malformations (Arteriovenous Malformation) 12/2021 - 04/2010
5	Telangiectasis (Telangiectasia) 12/2021 - 04/2010
5	Cardiovascular Diseases (Cardiovascular Disease) 09/2020 - 04/2017
4	Pre-Eclampsia (Preeclampsia) 04/2016 - 01/2012
4	Fibrosis (Cirrhosis) 01/2016 - 11/2002
4	Vascular Remodeling 01/2012 - 08/2005
3	Hemorrhage 01/2022 - 01/2018
3	Hypertension (High Blood Pressure) 01/2020 - 12/2008
3	Vascular Diseases (Vascular Disease) 01/2019 - 01/2018
3	Wounds and Injuries (Trauma) 04/2016 - 05/2004
3	Ureteral Obstruction 01/2016 - 11/2002
2	Epistaxis (Nosebleed) 01/2022 - 01/2019
2	Hypercholesterolemia 01/2019 - 01/2018
2	Hypoxia (Hypoxemia) 01/2007 - 07/2003
2	Necrosis 08/2006 - 03/2003
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2022
1	Rupture 01/2022
1	Pulmonary Arterial Hypertension 12/2021
1	Atherosclerosis 01/2019
1	Thrombasthenia (Glanzmann Thrombasthenia) 01/2018
1	Vascular System Injuries 04/2016
1	Communicable Diseases (Infectious Diseases) 03/2016
1	Brain Stem Infarctions (Weber Syndrome) 03/2016
1	Pulmonary Hypertension 01/2016
1	Neoplasm Metastasis (Metastasis) 08/2014
1	Breast Neoplasms (Breast Cancer) 08/2014
1	Chronic Renal Insufficiency 01/2014
1	Ischemia 11/2012
1	Vascular Malformations 10/2010
1	Esophageal Squamous Cell Carcinoma 12/2008
1	Choriocarcinoma 06/2008
1	Lewis Lung Carcinoma 01/2007
1	Reperfusion Injury 08/2006
1	Infarction (Infarctions) 05/2004
1	Kidney Diseases (Kidney Disease) 05/2002

Drug/Important Bio-Agent (IBA)

42	EndoglinIBA 01/2022 - 11/2002
9	Transforming Growth Factor beta (TGF-beta)IBA 04/2016 - 05/2002
6	Transforming Growth Factors (Transforming Growth Factor)IBA 08/2014 - 12/2008
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 07/2003
4	Activin Receptors (Activin Receptor)IBA 01/2022 - 03/2006
4	Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA 04/2010 - 05/2004
3	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2020 - 01/2012
3	IntegrinsIBA 01/2018 - 01/2014
3	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 10/2010 - 01/2007
3	Transforming Growth Factor beta1 (TGF beta 1)IBA 08/2006 - 11/2002
2	5' Untranslated Regions (5' UTR)IBA 04/2019 - 12/2011
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 04/2017 - 01/2007
2	Biomarkers (Surrogate Marker)IBA 04/2017 - 04/2010
2	Protein Isoforms (Isoforms)IBA 01/2016 - 12/2008
2	CytokinesIBA 01/2016 - 03/2003
2	Fibronectins (Fibronectin)IBA 01/2014 - 11/2002
2	CollagenIBA 01/2014 - 11/2002
2	Messenger RNA (mRNA)IBA 06/2008 - 11/2002
1	Blood Coagulation Factors (Coagulation Factor)IBA 01/2022
1	Nonsense Codon (Nonsense Mutation)IBA 12/2021
1	Actin Depolymerizing Factors (Cofilins)IBA 08/2021
1	MicroRNAs (MicroRNA)IBA 09/2020
1	RNA (Ribonucleic Acid)IBA 09/2020
1	Cell Surface ReceptorsIBA 06/2019
1	Apolipoproteins E (ApoE)IBA 01/2019
1	ApolipoproteinsIBA 01/2019
1	7-ketocholesterolIBA 01/2019
1	CholesterolIBA 01/2019
1	Glycoproteins (Glycoprotein)IBA 01/2019
1	LDL Receptors (LDL Receptor)IBA 01/2019
1	P-SelectinIBA 01/2019
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 04/2017
1	Matrix Metalloproteinases (MMPs)IBA 04/2016
1	Metalloproteases (Metalloproteinases)IBA 04/2016
1	Transcription Factors (Transcription Factor)IBA 04/2016
1	LA 803IBA 01/2014
1	Keratin-17 (Keratin 17)IBA 01/2014
1	ChemokinesIBA 01/2013
1	OxysterolsIBA 11/2012
1	DisulfidesIBA 01/2012
1	Protein Kinases (Protein Kinase)IBA 09/2011
1	betaglycan (TGFBR3)IBA 10/2009
1	T0901317IBA 06/2008
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2007
1	Adenosine Triphosphate (ATP)IBA 01/2007
1	Hemoglobins (Hemoglobin)IBA 01/2007
1	Adenosine Diphosphate (ADP)IBA 01/2007
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2007
1	Nitric Oxide Synthase (NO Synthase)IBA 08/2006
1	CreatinineIBA 08/2006
1	Caspase 3 (Caspase-3)IBA 07/2003
1	Caspase 8 (Caspase-8)IBA 07/2003
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2003
1	Laminin (Merosin)IBA 11/2002
1	Collagen Type IV (Type IV Collagen)IBA 11/2002

Therapy/Procedure

2	Therapeutics 01/2022 - 10/2009
1	Lasers (Laser) 01/2007
1	Ligation 11/2002